Program
eratrectinib
Also written as “VC004 Capsules”, “VC004 low dose” and “VC004 high dose”.
Its studies are mostly in Neoplasm Metastasis, led by Jiangsu vcare pharmaceutical technology.
Drug pageEratrectinib: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu vcare pharmaceutical technology | 62 open or running | phase 3since Oct 24, 2024 | Oct 12, 2020 | Dec 30, 2026phase 3 · NCT06658353 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 12, 2020First study: phase 2 study in Neoplasm MetastasisFirst studyNCT04614740 · 115 enrolled · China
- Sep 1, 2022Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT05528120 · 16 enrolled · China
- Jul 26, 2024Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT06529445 · 84 enrolled · China
- Sep 28, 2024Phase 1 study in Neoplasm MetastasisNCT06619951 · 56 enrolled · China
- Oct 24, 2024Phase 3 study in Locally Advanced Solid TumorNCT06658353 · 54 planned · China
- Jul 10, 2025Named eratrectinibINNProposed as its International Nonproprietary Name in WHO's List 133
- Jul 23, 2026Phase 1 study in Pain in Bone MetastasesNCT07731685 · 26 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Locally Advanced Solid TumorNCT06658353
- Dec 30, 2027Primary completion: phase 1 study in Pain in Bone MetastasesNCT07731685
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07731685Pain in Bone Metastases · China | 1 | Not yet recruiting | Dec 30, 2027 | 26 |
| NCT06658353Locally Advanced Solid Tumor · China | 3 | Recruiting | Dec 30, 2026 | 54 |
| NCT06619951Neoplasm Metastasis · China | 1 | Completed | Oct 31, 2024 | 56 |
| NCT06529445Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China | 1 | Completed | Aug 26, 2024 | 84 |
| NCT05528120Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China | 1 | Completed | Oct 28, 2022 | 16 |
| NCT04614740Neoplasm Metastasis · China | 2 | UNKNOWN | Jan 31, 2024 | 115 |
How it is read
Names in the registry
- “VC004 Capsules”, 3 entries
- “VC004 low dose”, 1 entry
- “VC004 high dose”, 1 entry
- “VC004 and Itraconazole”, 1 entry
- “VC004 and rifampicin”, 1 entry
Codes read as this program: VC004.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.